Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice

Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of multiple types of hematological malignancies, but have shown limited efficacy in patients with glioblastoma (GBM) or other solid tumors. This may be largely due to the immunosuppressive tumor microenvironment (TME) that com...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Xinyue, Ren, Jun, Amoozgar, Zohreh, Lee, Somin, Datta, Meenal, Roberge, Sylvie, Duquette, Mark, Fukumura, Dai, Jain, Rakesh K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008211/
https://www.ncbi.nlm.nih.gov/pubmed/36898734
http://dx.doi.org/10.1136/jitc-2022-005583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008211/
https://www.ncbi.nlm.nih.gov/pubmed/36898734
http://dx.doi.org/10.1136/jitc-2022-005583

Ejemplares similares